Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9204-1706 A · 1 trial · 2 indications
Count and % of events
| Arm | Type | Description |
|---|---|---|
| NNC9204-1706 A | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC9204-1706 A | DRUG | Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated. |
| Placebo | DRUG | Administered subcutaneously (s.c., under the skin) |
Inclusion Criteria: * Male subjects aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess of adipose tissue, as judged by the investigator Exclusion Criteria:...
NNC9204-1706 A is an investigational small molecule being developed for metabolism and nutrition disorders, specifically for overweight or obesity. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
NNC9204-1706 A is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO.
NNC9204-1706 A is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
NNC9204-1706 A has one completed Phase 1 trial, NCT03095807, which investigated single ascending doses in 34 male subjects who were overweight or had obesity. The trial was randomized, double-blind, and placebo-controlled, and took place in the United States.
No alternative names for NNC9204-1706 A have been disclosed. It is identified by its code name NNC9204-1706 A in clinical trial records.